LRRK2 and Parkinson disease: Studies based on genetic screening of patient cohorts comparing DBS-treated PD to patients not receiving DBS indicate that both certain forms of monogenic PD (LRRK2 and parkin) and carriers of the strong GBA risk alleles may be overrepresented in the DBS group.